Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew K Doherty

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Microorganisms|July 29, 2023
Alpha-Gal Bound Aptamer and Vancomycin Synergistically Reduce <i>Staphylococcus aureus</i> Infection In VivoMatthew K Doherty, Claire Shaw, Leslie Woods, et al.
Mbio|March 15, 2018
Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease PatientsMatthew K Doherty, Tao Ding, Charlie Koumpouras, et al.
Molecular Pharmaceutics|December 9, 2022
NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a Promising Safety MarginElke Lipka, Aaron M Chadderdon, Cheryl C Harteg, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Microorganisms|July 29, 2023
Alpha-Gal Bound Aptamer and Vancomycin Synergistically Reduce <i>Staphylococcus aureus</i> Infection In VivoMatthew K Doherty, Claire Shaw, Leslie Woods, et al.
Mbio|March 15, 2018
Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease PatientsMatthew K Doherty, Tao Ding, Charlie Koumpouras, et al.
Molecular Pharmaceutics|December 9, 2022
NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a Promising Safety MarginElke Lipka, Aaron M Chadderdon, Cheryl C Harteg, et al.
Pageof 1